


**IN THE CLAIMS:**

Please cancel claims 1-6, 9, 10, 19 and 20 without prejudice or disclaimer and amend the claims as shown below. A complete copy of the pending claims, after amendment, is attached as Appendix A.

04 Sub  
7. (Amended) A method of increasing sexual desire, interest or performance in a human [who is desirous thereof] in need of increased sexual desire, interest or performance, said method which comprises administering a sexually useful effective amount of a compound of the formula (A)



where

R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are the same or different and are:

-H,  
C<sub>1</sub>-C<sub>6</sub> alkyl,  
C<sub>3</sub>-C<sub>5</sub> alkenyl,  
C<sub>3</sub>-C<sub>5</sub> alkynyl,  
C<sub>3</sub>-C<sub>5</sub> cycloalkyl,  
C<sub>4</sub>-C<sub>10</sub> cycloalkyl,  
phenyl substituted C<sub>1</sub>-C<sub>6</sub> alkyl,

or -NR<sub>1</sub>R<sub>2</sub> [where R<sub>1</sub> and R<sub>2</sub> are cyclized with the attached nitrogen atom to produce] is a pyrrolidiyl, piperidiny, morphoninyl, 4-methyl piperazinyl or imidazolyl;

X is:

~~-H,  
C<sub>1</sub>-C<sub>6</sub> alkyl,  
-F, -Cl, -Br, -I,  
-OH,  
C<sub>1</sub>-C<sub>6</sub> alkoxy,  
cyano,  
carboxamide,  
carboxyl,  
(C<sub>1</sub>-C<sub>6</sub> alkoxy)carbonyl,~~

A is:

~~CH,  
CH<sub>2</sub>,  
CH-(halogen) where halogen is -F, -Cl, -Br, -I,  
CHCH<sub>3</sub>,  
C=O,  
C=S  
C-SCH<sub>3</sub>,  
C=NH,  
C-NH<sub>2</sub>  
C-NHCH<sub>3</sub>,  
C-NHCOOCH<sub>3</sub>,  
C-NHCN,  
SO<sub>2</sub>,  
N;~~

B is:

~~CH<sub>2</sub>,  
CH,  
CH-(halogen) where halogen is as defined above,  
C=O,  
N,  
NH,~~

N-CH<sub>3</sub>,

D is:

CH,

CH<sub>2</sub>,

CH-(halogen) where halogen is as defined above,

C=O,

O,

N,

NH,

N-CH<sub>3</sub>;

and n is 0 or 1, and where  $\text{---}$  is a single or double bond, with the provisos:

(1) that when n is 0, and

A is CH<sub>2</sub> CH-(halogen) where halogen is as defined above, CHCH<sub>3</sub>, C=O, C=S, C=NH, SO<sub>2</sub>;

then D is CH<sub>2</sub>, CH-(halogen) where halogen is as defined above, C=O, O, NH, N-CH<sub>3</sub>,

(2) that when n is 0, and

A is CH, C-SCH<sub>3</sub>, C-NH<sub>2</sub>, C-NHCH<sub>3</sub>, C-NHCOOCH<sub>3</sub>, C-NHCN, N; then

D is CH, N;

(3) that when n is 1, and

A is CH<sub>2</sub>, CH-(halogen) where halogen is as defined above, CHCH<sub>3</sub>, C=O, C=S, C=NH, SO<sub>2</sub>; and

B is CH<sub>2</sub>, CH-(halogen) where halogen is as defined above, C=O, NH, N-CH<sub>3</sub>; then

D is CH<sub>2</sub>, C=O, O, NH, N-CH<sub>3</sub>;

(4) that when n is 1, and

A is CH, C-SCH<sub>3</sub>, C-NH<sub>2</sub>, C-NHCH<sub>3</sub>, C-NHCOOCH<sub>3</sub>, C-NHCN, N; and

B is CH, N; then

D is CH<sub>2</sub>, C=O, O, NH, N-CH<sub>3</sub>;

(5) that when n is 1, and

ca  
cao

A is CH<sub>2</sub>, CHCH<sub>3</sub>, C=O, C=S, C=NH, SO<sub>2</sub>, and

B is CH, N; then

D is CH, N; and pharmaceutically acceptable salts thereof to the human.

B1  
con's

8. (Amended) The method [of increasing sexual desire, interest or performance in a human who is desirous thereof] according to claim 7 where the compound of formula (A) is (5R)-5-(methyldamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione.

---

11. (Original) The method according to claim 7 where the human is a male.

12. (Original) The method according to claim 7 where the human is female.

13. (Original) The method according to claim 7 where the compound of formula (A) or pharmaceutically acceptable salt thereof is administered orally, intranasally, buccally, intra-pulmonary, parenterally, or rectally.

14. (Original) The method according to claim 13 where the compound of formula (A) or pharmaceutically acceptable salt thereof is administered orally, intranasally, buccally, or intra-pulmonary.

15. (Original) The method according to claim 14 where the compound of formula (A) or pharmaceutically acceptable salt thereof is administered orally.

16. (Original) The method according to claim 7 where the sexually useful effective amount is from about 0.2 thru about 8 mg/person/dose.

17. (Original) The method according to claim 16 where the sexually useful effective amount is from about 0.5 thru about 5 mg/person/dose.

18. (Original) The method according to claim 17 where the sexually useful effective amount is from about 1 thru about 3 mg/person/dose.

*cont* *sub*  
21. (Original) The method according to claim 7 where the pharmaceutically acceptable salt is selected from the group consisting of salts of the following acids, methanesulfonic, hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, benzoic, citric, tartaric, fumaric, maleic,  $\text{CH}_3-(\text{CH}_2)_n-\text{COOH}$  where n is 0 thru 4, and  $\text{HOOC}-(\text{CH}_2)_n-\text{COOH}$  where n is as defined above.

22. (Original) The method according to claim 7 where the compound of formula (A) or pharmaceutically acceptable salt is administered from about 10 minutes to about 8 hr prior to sexual activity.

23. (Original) The method according to claim 22 where the compound of formula (A) pharmaceutically acceptable salt is administered from about 0.5 hr to about 1 hr prior to sexual activity.

24. (Original) The method according to claim 23 where the compound of formula (A) pharmaceutically acceptable salt is administered about 0.5 prior to sexual activity.

25. (Original) The method according to claim 7 where the human does not have Parkinson's disease.

26. (Original) The method according to claim 7 where the human does not experience postural hypotension.

27. (Original) The method according to claim 7 where the compound of formula (A) or pharmaceutically acceptable salt is used in combination with a sexually effective amount of one or more vascular smooth muscle relaxation agents where the compound of formula (A) or pharmaceutically acceptable salt is administered within 8

hours prior to sexual activity and where the vascular smooth muscle relaxation agent is administered to the human within a sexually effective time period prior to sexual activity.

---

28. (Amended) The method according to claim 27 where the vascular smooth muscle relaxation agent is selected from the group consisting of phosphodiesterase type 5 inhibitors, phosphodiesterase type 3 inhibitors, non-selective phosphodiesterase inhibitors, nitric oxide donor drugs, alpha type 1 adrenergic receptor antagonists, alpha type 2 adrenergic receptor antagonists, prostaglandin E1 receptor agonists [(PGE1)], and vasoactive intestinal polypeptide [(VIP)] agents.

*CS* *Sub*  
*CS* *CS* 29. (Amended) The method according to claim 28 where the vascular smooth muscle relaxation agent is selected from the group consisting of sildenafil, ICOS-351, milrinone, papaverine, linsidomine, phentolamine, yohimbine, [prostaglandin E1 (PGE1), and VIP] prostaglandin E1 receptor agonists, and vasoactive intestinal polypeptide agents.

---

*CS* *Sub*  
*CS* *CS* 30. (Original) The method according to claim 8 where the pharmaceutically acceptable salt of the compound is (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione malate.